$SBRA
Sabra Health Care REIT, Inc.

2023 Q2 Form 10-Q Financial Statement

#000149229823000014 Filed on May 03, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1
Revenue $161.2M $161.3M
YoY Change 3.34% -1.09%
Cost Of Revenue $43.96M $43.64M
YoY Change 29.21% 31.82%
Gross Profit $117.2M $117.7M
YoY Change -3.88% -9.47%
Gross Profit Margin 72.72% 72.95%
Selling, General & Admin $9.961M $10.29M
YoY Change 18.88% -5.31%
% of Gross Profit 8.5% 8.75%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $44.14M $52.83M
YoY Change -2.28% 16.73%
% of Gross Profit 37.66% 44.89%
Operating Expenses $58.87M $67.29M
YoY Change 0.81% 10.06%
Operating Profit $58.33M $50.40M
YoY Change -8.19% -26.81%
Interest Expense -$28.98M -$29.38M
YoY Change 3.29% 5.78%
% of Operating Profit -49.69% -58.29%
Other Income/Expense, Net -$7.833M -$22.72M
YoY Change 17.54% 11089.66%
Pretax Income $22.17M -$7.921M
YoY Change 13.16% -118.13%
Income Tax $326.0K $728.0K
% Of Pretax Income 1.47%
Net Earnings $21.19M -$9.487M
YoY Change 26.08% -123.37%
Net Earnings / Revenue 13.15% -5.88%
Basic Earnings Per Share $0.09 -$0.04
Diluted Earnings Per Share $0.09 -$0.04
COMMON SHARES
Basic Shares Outstanding 231.2M shares 231.2M shares
Diluted Shares Outstanding 232.2M shares 231.2M shares

Balance Sheet

Concept 2023 Q2 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $27.23M $33.53M
YoY Change -59.44% 35.01%
Cash & Equivalents $27.23M $33.53M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $173.9M $166.3M
YoY Change -29.56% -7.94%
LONG-TERM ASSETS
Property, Plant & Equipment $4.752B $4.797B
YoY Change -5.81% -6.96%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $140.4M $139.4M
YoY Change -36.16% 48.49%
Other Assets $5.146M $5.152M
YoY Change 17.81% 15.96%
Total Long-Term Assets $5.350B $5.390B
YoY Change -6.37% -5.51%
TOTAL ASSETS
Total Short-Term Assets $173.9M $166.3M
Total Long-Term Assets $5.350B $5.390B
Total Assets $5.524B $5.556B
YoY Change -7.33% -5.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $105.5M $121.6M
YoY Change 4.34% 30.9%
Accrued Expenses $16.40M $21.40M
YoY Change -1.2% -15.75%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $121.9M $143.0M
YoY Change 3.55% 20.88%
LONG-TERM LIABILITIES
Long-Term Debt $2.420B $2.397B
YoY Change -2.43% 1.66%
Other Long-Term Liabilities $38.69M $40.46M
YoY Change -15.54% -14.96%
Total Long-Term Liabilities $2.459B $2.437B
YoY Change -2.66% 1.33%
TOTAL LIABILITIES
Total Short-Term Liabilities $121.9M $143.0M
Total Long-Term Liabilities $2.459B $2.437B
Total Liabilities $2.581B $2.580B
YoY Change -2.39% 2.25%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock $2.312M $2.312M
YoY Change 0.09% 0.09%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.944B $2.976B
YoY Change
Total Liabilities & Shareholders Equity $5.524B $5.556B
YoY Change -7.33% -5.58%

Cashflow Statement

Concept 2023 Q2 2023 Q1
OPERATING ACTIVITIES
Net Income $21.19M -$9.487M
YoY Change 26.08% -123.37%
Depreciation, Depletion And Amortization $44.14M $52.83M
YoY Change -2.28% 16.73%
Cash From Operating Activities $70.33M $68.29M
YoY Change -8.15% 8.2%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $39.63M
YoY Change -292.63%
Acquisitions
YoY Change
Other Investing Activities -$8.193M $152.8M
YoY Change -90.98% -1016.7%
Cash From Investing Activities -$8.193M $113.2M
YoY Change -90.98% -403.89%
FINANCING ACTIVITIES
Cash Dividend Paid $69.35M
YoY Change 0.11%
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -68.47M -$196.1M
YoY Change -222.38% 74.26%
NET CHANGE
Cash From Operating Activities 70.33M $68.29M
Cash From Investing Activities -8.193M $113.2M
Cash From Financing Activities -68.47M -$196.1M
Net Change In Cash -6.337M -$14.61M
YoY Change -115.21% -83.14%
FREE CASH FLOW
Cash From Operating Activities $70.33M $68.29M
Capital Expenditures $0.00 $39.63M
Free Cash Flow $70.33M $28.66M
YoY Change -8.15% -65.75%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001492298
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2022#HealthCareResidentServiceMember
CY2023Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2022#HealthCareResidentServiceMember
CY2023Q1 us-gaap Derivative Asset Statement Of Financial Position Extensible Enumeration
DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration
http://www.sabrahealth.com/20230331#AccountsReceivablePrepaidExpensesDeferredFinancingCostsAndOtherAssetsNet
CY2022Q4 us-gaap Derivative Liability Statement Of Financial Position Extensible Enumeration
DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration
http://fasb.org/us-gaap/2022#AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent http://fasb.org/us-gaap/2022#LineOfCredit http://fasb.org/us-gaap/2022#LoansPayableToBank
CY2023Q1 us-gaap Derivative Asset Statement Of Financial Position Extensible Enumeration
DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration
http://www.sabrahealth.com/20230331#AccountsReceivablePrepaidExpensesDeferredFinancingCostsAndOtherAssetsNet
CY2022Q4 us-gaap Derivative Liability Statement Of Financial Position Extensible Enumeration
DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration
http://fasb.org/us-gaap/2022#AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent http://fasb.org/us-gaap/2022#LineOfCredit http://fasb.org/us-gaap/2022#LoansPayableToBank
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-34950
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
SABRA HEALTH CARE REIT, INC.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
MD
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-2560479
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
18500 Von Karman Avenue, Suite 550
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Irvine
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92612
CY2023Q1 dei City Area Code
CityAreaCode
888
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
393-8248
CY2023Q1 dei Security12b Title
Security12bTitle
Common stock, $.01 par value
CY2023Q1 dei Trading Symbol
TradingSymbol
SBRA
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
231195148 shares
CY2023Q1 us-gaap Real Estate Investment Property Accumulated Depreciation
RealEstateInvestmentPropertyAccumulatedDepreciation
952791000 usd
CY2022Q4 us-gaap Real Estate Investment Property Accumulated Depreciation
RealEstateInvestmentPropertyAccumulatedDepreciation
913345000 usd
CY2023Q1 us-gaap Real Estate Investment Property Net
RealEstateInvestmentPropertyNet
4797041000 usd
CY2022Q4 us-gaap Real Estate Investment Property Net
RealEstateInvestmentPropertyNet
4959343000 usd
CY2023Q1 sbra Financing Receivable And Other Investments Net
FinancingReceivableAndOtherInvestmentsNet
409079000 usd
CY2022Q4 sbra Financing Receivable And Other Investments Net
FinancingReceivableAndOtherInvestmentsNet
411396000 usd
CY2023Q1 us-gaap Equity Method Investments
EquityMethodInvestments
139402000 usd
CY2022Q4 us-gaap Equity Method Investments
EquityMethodInvestments
134962000 usd
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
33532000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
49308000 usd
CY2023Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
5152000 usd
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
4624000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
39369000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
40131000 usd
CY2023Q1 sbra Accounts Receivable Prepaid Expenses Deferred Financing Costs And Other Assets Net
AccountsReceivablePrepaidExpensesDeferredFinancingCostsAndOtherAssetsNet
132736000 usd
CY2022Q4 sbra Accounts Receivable Prepaid Expenses Deferred Financing Costs And Other Assets Net
AccountsReceivablePrepaidExpensesDeferredFinancingCostsAndOtherAssetsNet
147908000 usd
CY2023Q1 us-gaap Assets
Assets
5556311000 usd
CY2022Q4 us-gaap Assets
Assets
5747672000 usd
CY2023Q1 us-gaap Secured Debt
SecuredDebt
48754000 usd
CY2022Q4 us-gaap Secured Debt
SecuredDebt
49232000 usd
CY2023Q1 us-gaap Line Of Credit
LineOfCredit
79563000 usd
CY2022Q4 us-gaap Line Of Credit
LineOfCredit
196982000 usd
CY2023Q1 us-gaap Loans Payable To Bank
LoansPayableToBank
533657000 usd
CY2022Q4 us-gaap Loans Payable To Bank
LoansPayableToBank
526129000 usd
CY2023Q1 us-gaap Unsecured Debt
UnsecuredDebt
1734644000 usd
CY2022Q4 us-gaap Unsecured Debt
UnsecuredDebt
1734431000 usd
CY2023Q1 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
143002000 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
142259000 usd
CY2023Q1 us-gaap Below Market Lease Net
BelowMarketLeaseNet
40464000 usd
CY2022Q4 us-gaap Below Market Lease Net
BelowMarketLeaseNet
42244000 usd
CY2023Q1 us-gaap Liabilities
Liabilities
2580084000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
2691277000 usd
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
231195148 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
231195148 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
231009295 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
231009295 shares
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
2312000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
2310000 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4487707000 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4486967000 usd
CY2023Q1 us-gaap Accumulated Distributions In Excess Of Net Income
AccumulatedDistributionsInExcessOfNetIncome
1531230000 usd
CY2022Q4 us-gaap Accumulated Distributions In Excess Of Net Income
AccumulatedDistributionsInExcessOfNetIncome
1451945000 usd
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
17438000 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
19063000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
2976227000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
3056395000 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5556311000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5747672000 usd
CY2023Q1 us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
95870000 usd
CY2022Q1 us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
109886000 usd
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
56721000 usd
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
42227000 usd
CY2023Q1 us-gaap Interest And Fee Income Loans And Leases
InterestAndFeeIncomeLoansAndLeases
8733000 usd
CY2022Q1 us-gaap Interest And Fee Income Loans And Leases
InterestAndFeeIncomeLoansAndLeases
10992000 usd
CY2023Q1 us-gaap Revenues
Revenues
161324000 usd
CY2022Q1 us-gaap Revenues
Revenues
163105000 usd
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
52827000 usd
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
45256000 usd
CY2023Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
28540000 usd
CY2022Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
24972000 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10502000 usd
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10396000 usd
CY2023Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-208000 usd
CY2022Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
475000 usd
CY2023Q1 us-gaap Impairment Of Real Estate
ImpairmentOfRealEstate
7064000 usd
CY2022Q1 us-gaap Impairment Of Real Estate
ImpairmentOfRealEstate
0 usd
CY2023Q1 sbra Operating And Interest Expense
OperatingAndInterestExpense
146530000 usd
CY2022Q1 sbra Operating And Interest Expense
OperatingAndInterestExpense
119214000 usd
CY2023Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1541000 usd
CY2022Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-271000 usd
CY2023Q1 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
341000 usd
CY2022Q1 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
68000 usd
CY2023Q1 us-gaap Gains Losses On Sales Of Investment Real Estate
GainsLossesOnSalesOfInvestmentRealEstate
-21515000 usd
CY2022Q1 us-gaap Gains Losses On Sales Of Investment Real Estate
GainsLossesOnSalesOfInvestmentRealEstate
0 usd
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-22715000 usd
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-203000 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-7921000 usd
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
43688000 usd
CY2023Q1 sbra Income Loss From Equity Method Investments And Other Than Temporary Impairment
IncomeLossFromEquityMethodInvestmentsAndOtherThanTemporaryImpairment
-838000 usd
CY2022Q1 sbra Income Loss From Equity Method Investments And Other Than Temporary Impairment
IncomeLossFromEquityMethodInvestmentsAndOtherThanTemporaryImpairment
-2802000 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
728000 usd
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
284000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-9487000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
40602000 usd
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.18
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.18
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
231164876 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
230859993 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
231164876 shares
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
231564970 shares
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-9487000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
40602000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1623000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-644000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
-2000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
12339000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1625000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
11695000 usd
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11112000 usd
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
52297000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
3379530000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
40602000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
11695000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2673000 usd
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
-3484000 usd
CY2022Q1 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.30
CY2022Q1 us-gaap Dividends Common Stock
DividendsCommonStock
69493000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
3361523000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
3056395000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-9487000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1625000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2675000 usd
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
-1933000 usd
CY2023Q1 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.30
CY2023Q1 us-gaap Dividends Common Stock
DividendsCommonStock
69798000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
2976227000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-9487000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
40602000 usd
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
52827000 usd
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
45256000 usd
CY2023Q1 sbra Non Cash Rental And Related Revenues Adjustments
NonCashRentalAndRelatedRevenuesAdjustments
-2398000 usd
CY2022Q1 sbra Non Cash Rental And Related Revenues Adjustments
NonCashRentalAndRelatedRevenuesAdjustments
-4474000 usd
CY2023Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
392000 usd
CY2022Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
547000 usd
CY2023Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
3014000 usd
CY2022Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
2698000 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2229000 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2456000 usd
CY2023Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1541000 usd
CY2022Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-271000 usd
CY2023Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-208000 usd
CY2022Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
475000 usd
CY2023Q1 us-gaap Gains Losses On Sales Of Investment Real Estate
GainsLossesOnSalesOfInvestmentRealEstate
-21515000 usd
CY2022Q1 us-gaap Gains Losses On Sales Of Investment Real Estate
GainsLossesOnSalesOfInvestmentRealEstate
0 usd
CY2023Q1 us-gaap Impairment Of Real Estate
ImpairmentOfRealEstate
7064000 usd
CY2022Q1 us-gaap Impairment Of Real Estate
ImpairmentOfRealEstate
0 usd
CY2023Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-838000 usd
CY2022Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-2802000 usd
CY2023Q1 us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
367000 usd
CY2022Q1 us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
0 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2782000 usd
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
5457000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-5839000 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-20968000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
68289000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
63114000 usd
CY2023Q1 us-gaap Payments To Acquire Real Estate
PaymentsToAcquireRealEstate
39630000 usd
CY2022Q1 us-gaap Payments To Acquire Real Estate
PaymentsToAcquireRealEstate
20573000 usd
CY2023Q1 us-gaap Payments To Acquire Notes Receivable
PaymentsToAcquireNotesReceivable
1800000 usd
CY2022Q1 us-gaap Payments To Acquire Notes Receivable
PaymentsToAcquireNotesReceivable
0 usd
CY2023Q1 sbra Payments For Preferred Equity Investments
PaymentsForPreferredEquityInvestments
6384000 usd
CY2022Q1 sbra Payments For Preferred Equity Investments
PaymentsForPreferredEquityInvestments
4074000 usd
CY2023Q1 us-gaap Payments To Acquire Furniture And Fixtures
PaymentsToAcquireFurnitureAndFixtures
19540000 usd
CY2022Q1 us-gaap Payments To Acquire Furniture And Fixtures
PaymentsToAcquireFurnitureAndFixtures
10803000 usd
CY2023Q1 sbra Payments For Escrow Deposits For Potential Investments
PaymentsForEscrowDepositsForPotentialInvestments
0 usd
CY2022Q1 sbra Payments For Escrow Deposits For Potential Investments
PaymentsForEscrowDepositsForPotentialInvestments
3217000 usd
CY2023Q1 us-gaap Proceeds From Collection Of Notes Receivable
ProceedsFromCollectionOfNotesReceivable
6144000 usd
CY2022Q1 us-gaap Proceeds From Collection Of Notes Receivable
ProceedsFromCollectionOfNotesReceivable
696000 usd
CY2023Q1 sbra Repayments Of Preferred Equity Investments
RepaymentsOfPreferredEquityInvestments
-1433000 usd
CY2022Q1 sbra Repayments Of Preferred Equity Investments
RepaymentsOfPreferredEquityInvestments
-729000 usd
CY2023Q1 us-gaap Payments To Acquire Interest In Joint Venture
PaymentsToAcquireInterestInJointVenture
4797000 usd
CY2022Q1 us-gaap Payments To Acquire Interest In Joint Venture
PaymentsToAcquireInterestInJointVenture
0 usd
CY2023Q1 us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
152259000 usd
CY2022Q1 us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
0 usd
CY2023Q1 us-gaap Proceeds From Lease Payment Sales Type And Direct Financing Leases Investing Activity
ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity
25490000 usd
CY2022Q1 us-gaap Proceeds From Lease Payment Sales Type And Direct Financing Leases Investing Activity
ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity
0 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
113175000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-37242000 usd
CY2023Q1 us-gaap Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
-118442000 usd
CY2022Q1 us-gaap Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
16577000 usd
CY2023Q1 us-gaap Proceeds From Issuance Of Medium Term Notes
ProceedsFromIssuanceOfMediumTermNotes
12186000 usd
CY2022Q1 us-gaap Proceeds From Issuance Of Medium Term Notes
ProceedsFromIssuanceOfMediumTermNotes
0 usd
CY2023Q1 us-gaap Repayments Of Medium Term Notes
RepaymentsOfMediumTermNotes
0 usd
CY2022Q1 us-gaap Repayments Of Medium Term Notes
RepaymentsOfMediumTermNotes
40000000 usd
CY2023Q1 us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
490000 usd
CY2022Q1 us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
16067000 usd
CY2023Q1 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
18127000 usd
CY2022Q1 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
6000 usd
CY2023Q1 sbra Proceeds Payments From Issuance Of Stock Net Of Taxes Paid On Behalf Of Employees
ProceedsPaymentsFromIssuanceOfStockNetOfTaxesPaidOnBehalfOfEmployees
-1847000 usd
CY2022Q1 sbra Proceeds Payments From Issuance Of Stock Net Of Taxes Paid On Behalf Of Employees
ProceedsPaymentsFromIssuanceOfStockNetOfTaxesPaidOnBehalfOfEmployees
-3748000 usd
CY2023Q1 us-gaap Payments Of Dividends
PaymentsOfDividends
69351000 usd
CY2022Q1 us-gaap Payments Of Dividends
PaymentsOfDividends
69275000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-196071000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-112519000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-14607000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-86647000 usd
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-641000 usd
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
40000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
53932000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
115886000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
38684000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
29279000 usd
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
22318000 usd
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
18383000 usd
CY2023Q1 us-gaap Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1
NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
4644000 usd
CY2022Q1 us-gaap Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1
NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
5623000 usd
CY2022Q4 us-gaap Real Estate Investment Property Accumulated Depreciation
RealEstateInvestmentPropertyAccumulatedDepreciation
913345000 usd
CY2022Q4 us-gaap Real Estate Investment Property Net
RealEstateInvestmentPropertyNet
4959343000 usd
CY2023Q1 sbra Real Estate Investments Joint Ventures Number
RealEstateInvestmentsJointVenturesNumber
0 investment
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates.
CY2023Q1 us-gaap Real Estate Investment Property At Cost
RealEstateInvestmentPropertyAtCost
5749832000 usd
CY2023Q1 us-gaap Real Estate Investment Property Accumulated Depreciation
RealEstateInvestmentPropertyAccumulatedDepreciation
952791000 usd
CY2023Q1 us-gaap Real Estate Investment Property Net
RealEstateInvestmentPropertyNet
4797041000 usd
CY2022Q4 us-gaap Real Estate Investment Property At Cost
RealEstateInvestmentPropertyAtCost
5872688000 usd
CY2023Q1 us-gaap Buildings And Improvements Gross
BuildingsAndImprovementsGross
4945404000 usd
CY2022Q4 us-gaap Buildings And Improvements Gross
BuildingsAndImprovementsGross
5034470000 usd
CY2023Q1 us-gaap Fixtures And Equipment Gross
FixturesAndEquipmentGross
236032000 usd
CY2022Q4 us-gaap Fixtures And Equipment Gross
FixturesAndEquipmentGross
262644000 usd
CY2023Q1 us-gaap Land Improvements
LandImprovements
9499000 usd
CY2022Q4 us-gaap Land Improvements
LandImprovements
7085000 usd
CY2023Q1 us-gaap Land
Land
558897000 usd
CY2022Q4 us-gaap Land
Land
568489000 usd
CY2023Q1 us-gaap Real Estate Investment Property At Cost
RealEstateInvestmentPropertyAtCost
5749832000 usd
CY2022Q4 us-gaap Real Estate Investment Property At Cost
RealEstateInvestmentPropertyAtCost
5872688000 usd
CY2023Q1 us-gaap Real Estate Investment Property Accumulated Depreciation
RealEstateInvestmentPropertyAccumulatedDepreciation
952791000 usd
CY2022Q4 us-gaap Real Estate Investment Property Accumulated Depreciation
RealEstateInvestmentPropertyAccumulatedDepreciation
913345000 usd
CY2023Q1 us-gaap Real Estate Investment Property Net
RealEstateInvestmentPropertyNet
4797041000 usd
CY2022Q4 us-gaap Real Estate Investment Property Net
RealEstateInvestmentPropertyNet
4959343000 usd
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y
CY2023Q1 us-gaap Security Deposit Liability
SecurityDepositLiability
14000000 usd
CY2022Q4 us-gaap Security Deposit Liability
SecurityDepositLiability
13100000 usd
CY2023Q1 sbra Letters Of Credit Deposits
LettersOfCreditDeposits
59000000 usd
CY2022Q4 sbra Letters Of Credit Deposits
LettersOfCreditDeposits
57000000 usd
CY2023Q1 sbra Property Taxes Insurance And Tenant Improvement Deposit Liability
PropertyTaxesInsuranceAndTenantImprovementDepositLiability
13600000 usd
CY2022Q4 sbra Property Taxes Insurance And Tenant Improvement Deposit Liability
PropertyTaxesInsuranceAndTenantImprovementDepositLiability
13300000 usd
CY2023Q1 us-gaap Variable Lease Income
VariableLeaseIncome
3800000 usd
CY2022Q1 us-gaap Variable Lease Income
VariableLeaseIncome
5100000 usd
CY2023Q1 us-gaap Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year
LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear
279989000 usd
CY2023Q1 us-gaap Lessor Operating Lease Payments To Be Received Next Twelve Months
LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths
380057000 usd
CY2023Q1 us-gaap Lessor Operating Lease Payments To Be Received Two Years
LessorOperatingLeasePaymentsToBeReceivedTwoYears
375286000 usd
CY2023Q1 us-gaap Lessor Operating Lease Payments To Be Received Three Years
LessorOperatingLeasePaymentsToBeReceivedThreeYears
360133000 usd
CY2023Q1 us-gaap Lessor Operating Lease Payments To Be Received Four Years
LessorOperatingLeasePaymentsToBeReceivedFourYears
337235000 usd
CY2023Q1 sbra Lessor Operating Lease Payment To Be Received After Year Four
LessorOperatingLeasePaymentToBeReceivedAfterYearFour
1535962000 usd
CY2023Q1 us-gaap Lessor Operating Lease Payments To Be Received
LessorOperatingLeasePaymentsToBeReceived
3268662000 usd
CY2023Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
65000000 usd
CY2023Q1 us-gaap Equity Method Investments
EquityMethodInvestments
139402000 usd
CY2022Q4 us-gaap Equity Method Investments
EquityMethodInvestments
134962000 usd
CY2023Q1 us-gaap Impairment Of Real Estate
ImpairmentOfRealEstate
7100000 usd
CY2022Q1 us-gaap Impairment Of Real Estate
ImpairmentOfRealEstate
0 usd
CY2023Q1 sbra Disposal Group Including Discontinued Operations Number Of Properties
DisposalGroupIncludingDiscontinuedOperationsNumberOfProperties
8 facility
CY2022Q1 sbra Disposal Group Including Discontinued Operations Number Of Properties
DisposalGroupIncludingDiscontinuedOperationsNumberOfProperties
0 facility
CY2023Q1 us-gaap Disposal Group Including Discontinued Operation Consideration
DisposalGroupIncludingDiscontinuedOperationConsideration
160300000 usd
CY2022Q1 us-gaap Disposal Group Including Discontinued Operation Consideration
DisposalGroupIncludingDiscontinuedOperationConsideration
0 usd
CY2023Q1 sbra Disposal Group Including Discontinued Operation Assets And Liabilities Net
DisposalGroupIncludingDiscontinuedOperationAssetsAndLiabilitiesNet
181800000 usd
CY2022Q1 sbra Disposal Group Including Discontinued Operation Assets And Liabilities Net
DisposalGroupIncludingDiscontinuedOperationAssetsAndLiabilitiesNet
0 usd
CY2023Q1 us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
-21500000 usd
CY2022Q1 us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
0 usd
CY2023Q1 us-gaap Disposal Group Including Discontinued Operation Operating Income Loss
DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
-22100000 usd
CY2022Q1 us-gaap Disposal Group Including Discontinued Operation Operating Income Loss
DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
100000 usd
CY2023Q1 sbra Financing Receivable Number Of Loans
FinancingReceivableNumberOfLoans
13 loan
CY2023Q1 sbra Financing Receivable Principal Amount
FinancingReceivablePrincipalAmount
366200000 usd
CY2023Q1 us-gaap Notes Receivable Gross
NotesReceivableGross
362768000 usd
CY2022Q4 us-gaap Notes Receivable Gross
NotesReceivableGross
366936000 usd
CY2023Q1 sbra Financing Receivable Fixed Interest Rate
FinancingReceivableFixedInterestRate
0.076
CY2023Q1 sbra Financing Receivable Effective Interest Rate
FinancingReceivableEffectiveInterestRate
0.075
CY2023Q1 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
6403000 usd
CY2022Q4 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
6611000 usd
CY2023Q1 sbra Financing Receivable Principal Amount
FinancingReceivablePrincipalAmount
366200000 usd
CY2023Q1 us-gaap Notes Receivable Net
NotesReceivableNet
356365000 usd
CY2022Q4 us-gaap Notes Receivable Net
NotesReceivableNet
360325000 usd
CY2023Q1 sbra Preferred Equity Investments Number
PreferredEquityInvestmentsNumber
6 preferredequityinvestment
CY2023Q1 sbra Preferred Equity Investment Face Value
PreferredEquityInvestmentFaceValue
52551000 usd
CY2023Q1 sbra Preferred Equity Investment Carrying Amount
PreferredEquityInvestmentCarryingAmount
52714000 usd
CY2022Q4 sbra Preferred Equity Investment Carrying Amount
PreferredEquityInvestmentCarryingAmount
51071000 usd
CY2023Q1 sbra Preferred Equity Investment Weighted Average Contractual Rate
PreferredEquityInvestmentWeightedAverageContractualRate
0.109
CY2023Q1 sbra Preferred Equity Investment Weighted Average Effective Rate
PreferredEquityInvestmentWeightedAverageEffectiveRate
0.108
CY2023Q1 sbra Number Of Investments
NumberOfInvestments
19 investment
CY2023Q1 us-gaap Investment Owned Balance Principal Amount
InvestmentOwnedBalancePrincipalAmount
418751000 usd
CY2023Q1 sbra Financing Receivable And Other Investments Net
FinancingReceivableAndOtherInvestmentsNet
409079000 usd
CY2022Q4 sbra Financing Receivable And Other Investments Net
FinancingReceivableAndOtherInvestmentsNet
411396000 usd
CY2023Q1 sbra Investments Weighted Average Contractual Rate
InvestmentsWeightedAverageContractualRate
0.080
CY2023Q1 sbra Investments Weighted Average Effective Rate
InvestmentsWeightedAverageEffectiveRate
0.079
CY2022Q4 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
6611000 usd
CY2021Q4 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
6344000 usd
CY2023Q1 us-gaap Financing Receivable Allowance For Credit Losses Period Increase Decrease
FinancingReceivableAllowanceForCreditLossesPeriodIncreaseDecrease
-208000 usd
CY2023Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-208000 usd
CY2022Q1 us-gaap Financing Receivable Allowance For Credit Losses Period Increase Decrease
FinancingReceivableAllowanceForCreditLossesPeriodIncreaseDecrease
507000 usd
CY2023Q1 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
6403000 usd
CY2022Q1 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
6851000 usd
CY2023Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
28500000 usd
CY2022Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
25000000 usd
CY2023Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
3000000 usd
CY2022Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
2700000 usd
CY2023Q1 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
21400000 usd
CY2022Q4 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
18200000 usd
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
1489000 usd
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
2034000 usd
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
2089000 usd
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
502147000 usd
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
181769000 usd
CY2023Q1 sbra Long Term Debt Maturity After Year Four
LongTermDebtMaturityAfterYearFour
1730533000 usd
CY2023Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
2420061000 usd
CY2023Q1 us-gaap Debt Instrument Unamortized Discount Premium Net
DebtInstrumentUnamortizedDiscountPremiumNet
3719000 usd
CY2023Q1 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
19724000 usd
CY2023Q1 us-gaap Long Term Debt
LongTermDebt
2396618000 usd
CY2023Q1 us-gaap Derivative Liability Fair Value Gross Asset
DerivativeLiabilityFairValueGrossAsset
0 usd
CY2023Q1 us-gaap Derivative Liabilities
DerivativeLiabilities
0 usd
CY2023Q1 sbra Other Comprehensive Income Loss Cash Flow And Net Investment Hedge Gain Loss Before Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax
385000 usd
CY2022Q1 sbra Other Comprehensive Income Loss Cash Flow And Net Investment Hedge Gain Loss Before Reclassification And Tax
OtherComprehensiveIncomeLossCashFlowAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax
7153000 usd
CY2023Q1 us-gaap Derivative Fair Value Of Derivative Asset
DerivativeFairValueOfDerivativeAsset
19823000 usd
CY2023Q1 us-gaap Derivative Asset Fair Value Gross Liability
DerivativeAssetFairValueGrossLiability
0 usd
CY2023Q1 us-gaap Derivative Assets
DerivativeAssets
19823000 usd
CY2023Q1 us-gaap Derivative Collateral Obligation To Return Securities
DerivativeCollateralObligationToReturnSecurities
0 usd
CY2023Q1 us-gaap Derivative Collateral Obligation To Return Cash
DerivativeCollateralObligationToReturnCash
0 usd
CY2023Q1 us-gaap Derivative Fair Value Of Derivative Asset Amount Offset Against Collateral
DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral
19823000 usd
CY2023Q1 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
0 usd
CY2023Q1 us-gaap Derivative Collateral Right To Reclaim Securities
DerivativeCollateralRightToReclaimSecurities
0 usd
CY2023Q1 us-gaap Derivative Collateral Right To Reclaim Cash
DerivativeCollateralRightToReclaimCash
0 usd
CY2023Q1 us-gaap Derivative Fair Value Of Derivative Liability Amount Offset Against Collateral
DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral
0 usd
CY2022Q4 us-gaap Derivative Fair Value Of Derivative Asset
DerivativeFairValueOfDerivativeAsset
21477000 usd
CY2022Q4 us-gaap Derivative Asset Fair Value Gross Liability
DerivativeAssetFairValueGrossLiability
0 usd
CY2022Q4 us-gaap Derivative Assets
DerivativeAssets
21477000 usd
CY2022Q4 us-gaap Derivative Collateral Obligation To Return Securities
DerivativeCollateralObligationToReturnSecurities
0 usd
CY2022Q4 us-gaap Derivative Collateral Obligation To Return Cash
DerivativeCollateralObligationToReturnCash
0 usd
CY2022Q4 us-gaap Derivative Fair Value Of Derivative Asset Amount Offset Against Collateral
DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral
21477000 usd
CY2022Q4 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
0 usd
CY2022Q4 us-gaap Derivative Liability Fair Value Gross Asset
DerivativeLiabilityFairValueGrossAsset
0 usd
CY2022Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
0 usd
CY2022Q4 us-gaap Derivative Collateral Right To Reclaim Securities
DerivativeCollateralRightToReclaimSecurities
0 usd
CY2022Q4 us-gaap Derivative Collateral Right To Reclaim Cash
DerivativeCollateralRightToReclaimCash
0 usd
CY2022Q4 us-gaap Derivative Fair Value Of Derivative Liability Amount Offset Against Collateral
DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral
0 usd
CY2023Q1 sbra Financing Receivable Principal Amount
FinancingReceivablePrincipalAmount
366200000 usd
CY2022Q4 sbra Financing Receivable Principal Amount
FinancingReceivablePrincipalAmount
370364000 usd
CY2023Q1 sbra Preferred Equity Investment Face Value
PreferredEquityInvestmentFaceValue
52551000 usd
CY2022Q4 sbra Preferred Equity Investment Face Value
PreferredEquityInvestmentFaceValue
50902000 usd
CY2023Q1 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.30
CY2023Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1400000 usd
CY2022Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
3300000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-9487000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
40602000 usd
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
231164876 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
230859993 shares
CY2023Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0 shares
CY2022Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
704977 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
231164876 shares
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
231564970 shares
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.18
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.18

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0001492298-23-000014-index-headers.html Edgar Link pending
0001492298-23-000014-index.html Edgar Link pending
0001492298-23-000014.txt Edgar Link pending
0001492298-23-000014-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
sbra-20230331.htm Edgar Link pending
sbra-20230331.xsd Edgar Link pending
sbraex3112023q1.htm Edgar Link pending
sbraex3122023q1.htm Edgar Link pending
sbraex3212023q1.htm Edgar Link pending
sbraex3222023q1.htm Edgar Link pending
Show.js Edgar Link pending
sbra-20230331_cal.xml Edgar Link unprocessable
sbra-20230331_def.xml Edgar Link unprocessable
sbra-20230331_lab.xml Edgar Link unprocessable
sbra-20230331_pre.xml Edgar Link unprocessable
sbra-20230331_htm.xml Edgar Link completed